Characterization of E. coli-specific T cells in Crohn's disease

克罗恩病中大肠杆菌特异性 T 细胞的表征

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT Several lines of evidence have implicated T cells in the pathogenesis of Crohn's disease, an uncontrolled inflammatory condition of the intestines in which immune cells overreact to the bacteria that live there. Previous studies of antigen-nonspecific T cells in Crohn's disease have not identified overall differences in them that would explain this over reactivity. However, we have recently identified CD4 T cells of the immune system that can react to a peptide from protein antigen (OmpC) made by one such bacteria (E. coli), to which antibodies are commonly seen only in people with Crohn's disease. We found that these OmpC-specific cells make IL-10 unless they come from Crohn's disease patients, and hypothesize that this defect plays a central role in the inflammation of Crohn's disease. IL-10 is a cytokine that clearly plays a central role in limiting inflammation in the intestines, because mice without the IL-10 gene and humans born with a mutation in the receptor for IL-10 both quickly develop severe enterocolitis, resembling Crohn's disease. The overall goal of the studies proposed here is to determine why these gut flora antigen-specific T cells fail to make IL-10 in Crohn's disease, as a mechanism by which tolerance to gut flora is lost in this condition. The novel approach is to integrate single cell gene expression and epigenetic analyses in these OmpC-specific T cells we can isolate with MHC-II tetramers. The hypothesis will be addressed in two Specific Aims with genome-wide expression differences correlated with IL-10 expression in Aim 1, and an epigenetic basis for failed IL-10 expression in Crohn's disease to be revealed in Aim 2. Together these studies will advance our understanding of abnormal IL-10 regulation by gut microbial antigen-specific T cells in Crohn's disease, and provide the foundation for determining how such a defect contributes to disease pathogenesis.
项目总结/摘要 几条证据表明T细胞参与了克罗恩病的发病机制,克罗恩病是一种无法控制的疾病, 肠道的炎症状态,免疫细胞对肠道内的细菌反应过度。 以前对克罗恩病中抗原非特异性T细胞的研究尚未确定 他们可以解释这种过度反应。然而,我们最近发现了免疫系统中的CD 4 T细胞, 可以与来自蛋白质抗原(OmpC)的肽反应的系统(E.大肠杆菌),其中 抗体通常只在克罗恩病患者中可见。我们发现这些OmpC特异性细胞 除非它们来自克罗恩病患者,否则它们不会产生IL-10,并假设这种缺陷在克罗恩病患者中起着核心作用。 在克罗恩病炎症中的作用。IL-10是一种细胞因子,其在限制肿瘤细胞增殖中明显起着核心作用。 肠道炎症,因为没有IL-10基因的小鼠和出生时具有IL-10基因突变的人类, IL-10受体的受试者都迅速发展为严重的小肠结肠炎,类似于克罗恩病。的总目标 这里提出的研究是要确定为什么这些肠道植物群抗原特异性T细胞不能产生IL-10, 克罗恩病,作为一种机制,其中耐受肠道植物群是在这种情况下失去。这种新方法 是在这些OmpC特异性T细胞中整合单细胞基因表达和表观遗传分析, 用MHC-II四聚体分离。这一假设将在两个特定的目的与全基因组 表达差异与Aim 1中IL-10表达相关,以及IL-10失败的表观遗传基础 在克罗恩病中的表达将在Aim 2中揭示。这些研究将共同推进我们对 肠道微生物抗原特异性T细胞对克罗恩病中IL-10的异常调节, 确定这种缺陷如何有助于疾病发病机制的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Daniel Lord其他文献

James Daniel Lord的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Daniel Lord', 18)}}的其他基金

Characterization of E. coli-specific T cells in Crohn's disease
克罗恩病中大肠杆菌特异性 T 细胞的表征
  • 批准号:
    10558631
  • 财政年份:
    2022
  • 资助金额:
    $ 25.95万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    8141666
  • 财政年份:
    2008
  • 资助金额:
    $ 25.95万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    7808332
  • 财政年份:
    2008
  • 资助金额:
    $ 25.95万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    7513622
  • 财政年份:
    2008
  • 资助金额:
    $ 25.95万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    8077443
  • 财政年份:
    2008
  • 资助金额:
    $ 25.95万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    8317680
  • 财政年份:
    2008
  • 资助金额:
    $ 25.95万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    7676870
  • 财政年份:
    2008
  • 资助金额:
    $ 25.95万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 25.95万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 25.95万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 25.95万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 25.95万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 25.95万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 25.95万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 25.95万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 25.95万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 25.95万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 25.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了